Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615001027505
Ethics application status
Approved
Date submitted
18/05/2015
Date registered
1/10/2015
Date last updated
10/02/2022
Date data sharing statement initially provided
10/02/2022
Date results provided
10/02/2022
Type of registration
Prospectively registered

Titles & IDs
Public title
Effect of Nitrates on Bone Density
Scientific title
Efficacy of nitrates on bone mineral density in postmenopausal women with osteopenia
Secondary ID [1] 286735 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Osteoporosis 295097 0
Condition category
Condition code
Musculoskeletal 295343 295343 0 0
Osteoporosis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Arm 1, isosorbide mononitrate 20mg daily, immediate release, oral for 1 year then no intervention for 1 year
Arm 2, isosorbide mononitrate 30mg daily, sustained release, oral for 1 year then no intervention for 1 year
Arm 3, isosorbide mononitrate 60mg daily, sustained release, oral for 1 year then no intervention for 1 year
Arm 4, nitroglycerin 25 mg daily, transdermal for 1 year then no intervention for 1 year
Arm 5, nitroglycerin 50 mg daily, transdermal for 1 year then no intervention for 1 year

Treatment adherence will be monitored in the trial by count of tablet or patches returned at the 6 month and 1 year visits.
Intervention code [1] 291890 0
Treatment: Drugs
Intervention code [2] 292894 0
Prevention
Comparator / control treatment
Arm 6 Placebo, tablet daily for 1 year then no intervention for 1 year
Arm 7 Placebo, patch daily for 1 year then no intervention for 1 year
Control group
Placebo

Outcomes
Primary outcome [1] 295094 0
Change in lumbar spine bone mineral density assessed on DXA scans
Timepoint [1] 295094 0
1 year
Secondary outcome [1] 314752 0
Change in total hip bone mineral density assessed on DXA scans
Timepoint [1] 314752 0
1 year
Secondary outcome [2] 314753 0
Change in femoral neck bone mineral density assessed on DXA scans
Timepoint [2] 314753 0
1 year
Secondary outcome [3] 314754 0
Change in total body bone mineral density assessed on DXA scans
Timepoint [3] 314754 0
1 year
Secondary outcome [4] 314755 0
Change in markers of bone turnover (procollagen type-I N-terminal propeptide, P1NP, and Beta-C-terminal telopeptide of type I collagen, CTX, assessed using via serum assay)
Timepoint [4] 314755 0
1 year
Secondary outcome [5] 314757 0
Change in markers of bone turnover (procollagen type-I N-terminal propeptide, P1NP, and Beta-C-terminal telopeptide of type I collagen, CTX, assessed using via serum assay)
Timepoint [5] 314757 0
2 years
Secondary outcome [6] 314758 0
Change in lumbar spine bone mineral density assessed on DXA scans
Timepoint [6] 314758 0
2 years
Secondary outcome [7] 314759 0
Change in total hip bone mineral density assessed on DXA scans
Timepoint [7] 314759 0
2 years
Secondary outcome [8] 314760 0
Change in femoral neck bone mineral density assessed on DXA scans
Timepoint [8] 314760 0
2 years
Secondary outcome [9] 314761 0
Change in total body bone mineral density assessed on DXA scans
Timepoint [9] 314761 0
2 years

Eligibility
Key inclusion criteria
1. Postmenopausal women aged >55 years
2. Bone mineral density T score at the lumbar spine, femoral neck or total hip between -1 and -2.5
Minimum age
55 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Bone mineral density T score <-2.5 at the total hip, femoral neck or lumbar spine
2. Current use of nitrate agents, or phosphodiesterase-5 inhibitors
3. Concurrent major systemic illness including untreated hypothyroidism or hyperthyroidism, chronic liver disease, chronic renal failure, malignancy, and active major gastrointestinal disease
4. Known congenital heart disease or hypotension, systolic blood pressure < 100 mmHg
5. Metabolic bone disease
6. Previous fragility fracture of the hip or clinical spine fracture
7. Current or past use of bisphosphonate therapy within 12 months, or any past zoledronate use
8. Use of oral glucocorticoid drugs equivalent to an average dose of at least prednisone 2.5mg/day during the preceding 6 months
9. Use of hormone replacement therapy within 12 months
10. Known nitrate hypersensitivity

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Numbered containers
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation with blocks of varying size.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
30/11/2015
Actual
20/09/2016
Date of last participant enrolment
Anticipated
Actual
30/10/2017
Date of last data collection
Anticipated
Actual
31/10/2018
Sample size
Target
240
Accrual to date
Final
240
Recruitment outside Australia
Country [1] 6886 0
New Zealand
State/province [1] 6886 0

Funding & Sponsors
Funding source category [1] 291287 0
Government body
Name [1] 291287 0
Health Research Council of New Zealand
Country [1] 291287 0
New Zealand
Primary sponsor type
University
Name
University of Auckland
Address
Private Bag 92019,
Auckland, 1142
New Zealand
Country
New Zealand
Secondary sponsor category [1] 289965 0
None
Name [1] 289965 0
Address [1] 289965 0
Country [1] 289965 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292853 0
Northern B Health and Disability Ethics Committee
Ethics committee address [1] 292853 0
Ethics committee country [1] 292853 0
New Zealand
Date submitted for ethics approval [1] 292853 0
18/05/2015
Approval date [1] 292853 0
09/06/2015
Ethics approval number [1] 292853 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 57350 0
A/Prof Mark Bolland
Address 57350 0
Department of Medicine University of Auckland Private Bag 92019 Auckland 1142
Country 57350 0
New Zealand
Phone 57350 0
64 9 373 7599
Fax 57350 0
64 9 373 7677
Email 57350 0
[email protected]
Contact person for public queries
Name 57351 0
Anne Horne
Address 57351 0
Department of Medicine University of Auckland Private Bag 92019 Auckland 1142
Country 57351 0
New Zealand
Phone 57351 0
64 9 373 7599
Fax 57351 0
64 9 373 7677
Email 57351 0
[email protected]
Contact person for scientific queries
Name 57352 0
Mark Bolland
Address 57352 0
Department of Medicine University of Auckland Private Bag 92019 Auckland 1142
Country 57352 0
New Zealand
Phone 57352 0
64 9 373 7599
Fax 57352 0
64 9 373 7677
Email 57352 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers upon reasonable request

Conditions for requesting access:
• -

What individual participant data might be shared?
• All requested data from the trial

What types of analyses could be done with individual participant data?
• All analyses

When can requests for individual participant data be made (start and end dates)?
From:
From trial publication on pubmed (5/7/20) onwards with no end date

To:
-

Where can requests to access individual participant data be made, or data be obtained directly?
• By contacting lead author by email ([email protected])

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseNitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial.2020https://dx.doi.org/10.1002/jbmr.3982
N.B. These documents automatically identified may not have been verified by the study sponsor.